Seventh...the first few minutes after I realized MS was taken off the pipeline flow-chart I was bit concerned. But after thinking about the totality of circumstances I became much more positive that something is/has been going on concerning 2-73,MS and Biogen. There is no other explanation. The whole Klamer thing really tipped me off. You dont tout 2-73 for MS just 2 weeks ago at a partnership conference in Boston, then completely remove it because of failure 2 weeks later. If it failed testing by Biogen, Anavex would have known this months ago - well before the Partnership Conference in Boston 2 weeks ago, as Biogen has had 2-73 in their lab for almost a year...more than enough time to tell if it "works" or doesn't. The other factor is the Wayne State Presentation at the end of October in regards to Sigma 1 and MS/Remyelination.
I hate speculating, but I don't even think this is speculation at this point, that someone, probably Biogen, is taking over the 2-73 preclinicals for MS.
-Fireman
News 
Market Data 
Discover 
AI
